Sahay Sandeep, Balasubramanian Vijay, Memon Humna, Poms Abby, Bossone Eduardo, Highland Kristine, Kay Dana, Levine Deborah J, Mullin Christopher J, Melendres-Groves Lana, Mathai Stephen C, Soto Francisco J, Shlobin Oksana, Elwing Jean M
Division of Pulmonary Critical Care & Sleep Medicine Houston Methodist Hospital Houston Texas USA.
Division of Pulmonary & Critical Care Medicine UCSF Fresno Fresno California USA.
Pulm Circ. 2022 Apr 8;12(2):e12057. doi: 10.1002/pul2.12057. eCollection 2022 Apr.
Pulmonary arterial hypertension (PAH) is a chronically progressive fatal disease. A goal-oriented approach to achieve low risk status has been associated with improved survival. A variety of risk stratification tools are available, but use is low. We conducted a survey to assess potential reasons for under-utilization. We conducted a survey-based study of global PAH disease specialists with a goal of assessing risk assessment utilization and identifying modifiable barriers to use. The survey was designed by the American College of Chest Physicians' Pulmonary Vascular Diseases (PVD) NetWork. Respondents were global members of the PVD NetWork and Pulmonary Hypertension Association. Survey invitations were sent electronically to all members. Participation was anonymous and no provider or patient level data was collected. Participants from four countries responded with the majority (84%) being from the United States. Our survey found suboptimal use of any risk stratification tool with 71/112 (63%) reporting use. A total of 85% of the respondents had more than 5 years of experience in managing PAH. REVEAL 2.0 and European Society of Cardiology/European Respiratory Society risk tools were the most commonly used. A total of 44 (65%) surveyed felt that use of risk tools led to change in PAH therapies. Only 6 (9%) felt they prompted additional testing or changed the frequency of follow-up. A total of 5 (7%) reported they prompted goals of care/palliative care discussions and 2 (3%) that they triggered lung transplant referral. The vast majority indicated that incorporation of risk tools into electronic medical records (EMR) would improve utilization. PAH risk assessment tools remain under-utilized. Most respondents were experienced PAH clinicians. More than one-third were not routinely using risk tools. Most felt that risk tools led to PAH therapy changes but few reported impacts on other aspects of care. The most commonly identified barriers to use were time constraints and lack of integration with EMR.
肺动脉高压(PAH)是一种慢性进行性致命疾病。采用以目标为导向的方法来实现低风险状态与生存率提高相关。有多种风险分层工具可供使用,但使用率较低。我们进行了一项调查,以评估使用不足的潜在原因。我们对全球PAH疾病专家进行了一项基于调查的研究,目的是评估风险评估的使用情况并确定可改变的使用障碍。该调查由美国胸科医师学会肺血管疾病(PVD)网络设计。受访者是PVD网络和肺动脉高压协会的全球成员。调查邀请通过电子邮件发送给所有成员。参与是匿名的,未收集提供者或患者层面的数据。来自四个国家的参与者做出了回应,其中大多数(84%)来自美国。我们的调查发现,任何风险分层工具的使用都不理想,71/112(63%)的受访者报告使用过。共有85%的受访者在管理PAH方面有超过5年的经验。REVEAL 2.0和欧洲心脏病学会/欧洲呼吸学会风险工具是最常用的。共有44名(65%)受访者认为使用风险工具导致了PAH治疗的改变。只有6名(9%)受访者认为它们促使进行了额外的检查或改变了随访频率。共有5名(7%)受访者报告说它们促使了对护理目标/姑息治疗的讨论,2名(3%)受访者报告说它们触发了肺移植转诊。绝大多数受访者表示,将风险工具纳入电子病历(EMR)将提高使用率。PAH风险评估工具的使用仍然不足。大多数受访者是经验丰富的PAH临床医生。超过三分之一的人没有常规使用风险工具。大多数人认为风险工具导致了PAH治疗的改变,但很少有人报告对护理的其他方面有影响。最常见的使用障碍是时间限制和与EMR缺乏整合。